DRG Epidemiology’s coverage of hemophilia comprises epidemiological estimates of key patient populations in the mature (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey), as well as countries in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. We report the diagnosed prevalence of hemophilia for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s hemophilia forecast will answer the following questions:

  • Of all people with hemophilia, how many in each country have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of  hemophilia over the forecast period?
  • How many people with diagnosed hemophilia are inhibitor-positive?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following hemophilia patient populations:

  • Prevalent cases by diagnosis status.
  • Diagnosed prevalent cases by severity.
  • Inhibitor status by severity.

Table of contents

  • Hemophilia - Epidemiology - Americas Data
    • Introduction
      • Key Findings
        • Overview
          • Prevalence of Hemophilia per 100,000 Among People of All Ages in 2017 and 2027
          • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Hemophilia over the Next Ten Years
          • Number of Additional Prevalent Cases of Hemophilia in 2027 in the Countries Under Study due to Trends in Risk or Survival
      • Epidemiology Data
      • Methods
        • Diagnosed Prevalence
        • Severity Status
        • Inhibitor Status by Severity
        • Inhibitor Titer
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Hemophilia
          • Studies Excluded from the Analysis of Hemophilia
        • Risk/Protective Factors
          • Risk/Protective Factors for Hemophilia
        • Bibliography

    Author(s): Abey John, MPH

    Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

    Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

    Related Reports

    Hemophilia - Current Treatment - Detailed, Expanded Analysis (EU)

    Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are used: (1) prophylaxis,...

    View Details

    Hemophilia - Landscape & Forecast - Disease Landscape & Forecast

    DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options an...

    View Details

    Hemophilia - Unmet Need - Detailed, Expanded Analysis : Hemophilia A – Severe Without Inhibitors: US/EU

    The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatme...

    View Details

    Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2020

    DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With...

    View Details